UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2020

PRECIGEN, INC.
(Exact name of registrant as specified in its charter)

Virginia	001-36042	26-0084895
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

20374 Seneca Meadows Parkway, Germantown, Maryland 20876
(Address of principal executive offices) (Zip Code)

(301) 556-9900
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, No Par Value	**PGEN**	**Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 2, 2020, reporting its financial results for the quarter and year ended December 31, 2019.

This information, including the Exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On March 2, 2020, Precigen, Inc. provided a slide presentation to accompany its press release. A copy of the presentation is furnished as Exhibit 99.2 hereto.

This information, including the Exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated March 2, 2020
99.2	Slide presentation of Precigen, Inc. dated March 2, 2020
104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Precigen, Inc.

By: /s/ Rick L. Sterling
Rick L. Sterling
Chief Financial Officer

Dated: March 2, 2020

Precigen Reports Fourth Quarter and Year End 2019 Financial Results

– Company completed series of transactions to support tighter focus on healthcare –

– Quarterly GAAP revenues from continuing operations of $17.0 million and net loss attributable to Precigen of $169.2 million, of which $95.7 million was from discontinued operations and an additional $33.8 million was for non-cash charges related to continuing operations –

GERMANTOWN, MD, March 2, 2020 – Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced its fourth quarter financial results for 2019.

Recent Business Highlights:

- The Company announced the appointment of Helen Sabzevari, PhD as President and CEO of Precigen and Randal J. Kirk as Executive Chairman effective as of January 1, 2020. The Company also changed its name to Precigen, Inc. from Intrexon Corporation and its Nasdaq stock symbol to PGEN from XON effective February 1, 2020;
- The Company closed sales of a number of its assets for an aggregate of $65.2 million and sold $35 million of its common stock in January 2020, thereby alleviating the going concern qualification associated with its 2019 consolidated financial statements as well as further streamlining corporate focus;
- The Company sold its ownership stake in AquaBounty Technologies, Inc. (Nasdaq: AQB) in October 2019 for proceeds of $21.6 million;
- Precigen announced that the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform for patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261);
- Precigen ActoBio, Inc., a wholly-owned subsidiary of Precigen, collaboration partner Oragenics, Inc. (NYSE American: OGEN) completed enrollment in the Phase 2 trial of AG013, an easy to use oral rinsing system designed to prevent and treat oral mucositis; and
- Triple-Gene LLC, a majority-owned subsidiary of Precigen, completed the Phase 1 trial enrollment and reported preliminary data of its investigational multigenic gene therapy INXN-4001 for the treatment of heart failure.

Fourth Quarter 2019 Financial Highlights:

- Total revenues from continuing operations of $17.0 million;
- Net loss of $169.2 million attributable to Precigen, or $(1.09) per basic share, of which $95.7 million was from discontinued operations and an additional $33.8 million was for non-cash charges related to continuing operations; and
- Cash, cash equivalents, and short-term investments for continuing operations totaled $75.1 million at December 31, 2019.

Full Year 2019 Financial Highlights:

- Total revenues from continuing operations of $90.7 million;
- Net loss of $322.3 million attributable to Precigen, or $(2.09) per basic share, of which $116.2 million was from discontinued operations and an additional $70.4 million was for non-cash charges related to continuing operations.

“I am confident that we will make important advances this year in our mission to improve patient care through innovative gene and cell therapies,” said Dr. Sabzevari. “We enter 2020 with cash resources that we believe are sufficient for us to deliver on several value-creating milestones during the year across our clinical pipeline. At the same time, we are laser-focused on aligning our portfolio, streamlining operations and maximizing organizational structures to improve operational efficiency going forward.”

Fourth Quarter 2019 Financial Results Compared to Prior Year Period

Total revenues decreased $24.2 million from the quarter ended December 31, 2018. Collaboration and licensing revenues decreased $24.6 million, or 103%, from the quarter ended December 31, 2018 primarily due to the reacquisition of rights previously licensed to some of Precigen’s collaborators in the second half of 2018 and the result of which eliminated or substantially reduced revenues previously generated from those collaborations. Additionally, collaboration and licensing revenues from collaborations with other collaborators decreased due to lower demand for research and development services in the current year period.

Research and development expenses decreased $252.2 million, or 92%. The 2018 amounts include a $228.0 million expense related to in-process research and development reacquired from former collaborators. Selling, general and administrative (SG&A) expenses increased $6.3 million, or 28% which was primarily attributable to increased compensation expenses related to performance and retention incentives for SG&A employees, partially offset by (i) decreased share-based compensation expense which arose primarily from the departure of former employees during the first half of the current year; and (ii) fewer legal fees associated with the Company’s Trans Ova subsidiary. The Company also recorded a $29.6 million goodwill impairment charge in the fourth quarter of 2019 related to its Trans Ova subsidiary.

Full Year 2019 Financial Results Compared to Prior Year Period

Total revenues decreased $60.5 million from the year ended December 31, 2018. Collaboration and licensing revenues decreased $55.5 million, or 80%, from the year ended December 31, 2018 primarily due to the reacquisition of rights previously licensed to some of Precigen’s collaborators in the second half of 2018 and the result of which eliminated or substantially reduced revenues previously generated from those collaborations. Additionally, in 2018, the Company recognized additional revenues from the acceleration of previously deferred revenue upon mutual termination of certain collaborations. Product revenues decreased $4.7 million, or 17%, primarily due to lower customer demand in the beef and dairy industries resulting in fewer sales of pregnant cows and calf products. Gross margin on products also declined in the current period as a result of fewer products sold.

Research and development expenses decreased $264.4 million, or 72%. The 2018 amounts include $236.7 million of expenses related to in-process research and development reacquired from former collaborators. SG&A expenses decreased $24.9 million, or 20%. SG&A salaries, benefits, and other personnel costs decreased $14.9 million primarily due to decreased share-based compensation expense as a result of the reversal of previously recognized expense for unvested options granted to former employees as well as the conclusion of the vesting period for other previously granted stock options. Legal and professional fees decreased $6.1 million primarily due to fewer legal fees associated with the Company’s Trans Ova subsidiary. The Company also recorded a $29.6 million goodwill impairment charge in the fourth quarter of 2019 related to its Trans Ova subsidiary.

Conference Call and Webcast

Precigen will host a conference call today Monday March 2nd at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1-412-317-6061 (International) and providing the number 4230814 to join the Precigen Conference Call. Participants may also access the live webcast through Precigen's website in the Events section at https://investors.precigen.com/press-events/event-calendar.

Precigen: Advancing Medicine with Precision™

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

Trademarks

Precigen, UltraCAR-T, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical and clinical trials and discovery programs, the promise of the Company's portfolio of therapies, the Company's refocus to a healthcare-oriented business, and its continuing evaluation of options for the Company's non-healthcare businesses. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

For more information, contact:

Investor Contact:

Steven Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com

Corporate Contact:

Marie Rossi, PhD
Vice President, Communications
Tel: +1 (301) 556-9850
press@precigen.com

Precigen, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)

(Amounts in thousands)	December 31, 2019	December 31, 2018
Assets		
Current assets		
Cash and cash equivalents	$ 65,793	$ 96,876
Restricted cash	—	6,987
Short-term investments	9,260	119,614
Equity securities	—	384
Receivables		
Trade, net	20,650	21,179
Related parties, net	600	4,129
Other, net	4,978	1,257
Inventory	16,097	20,575
Prepaid expenses and other	6,444	5,327
Current assets held for sale	110,821	9,155
Total current assets	234,643	285,483
Equity securities, noncurrent	—	640
Property, plant and equipment, net	60,969	86,896
Intangible assets, net	68,346	88,962
Goodwill	63,754	93,627
Investments in affiliates	1,461	2,139
Right-of-use assets	25,228	—
Other assets	1,362	2,069
Noncurrent assets held for sale	—	156,361
Total assets	$ 455,763	$ 716,177
Current liabilities		
Accounts payable	$ 5,917	$ 11,973
Accrued compensation and benefits	14,091	9,955
Other accrued liabilities	12,049	19,005
Deferred revenue	5,697	11,088
Lines of credit	1,922	466
Current portion of long-term debt	31,670	479
Current portion of lease liabilities	4,182	—
Related party payables	51	256
Current liabilities held for sale	47,333	8,340
Total current liabilities	122,912	61,562
Long-term debt, net of current portion	186,321	211,216
Deferred revenue, net of current portion	48,136	46,728
Lease liabilities, net of current portion	23,849	—
Deferred tax liabilities, net	2,834	3,856
Other long-term liabilities	—	3,135
Long-term liabilities held for sale	—	10,958
Total liabilities	384,052	337,455
Commitments and contingencies		
Total equity		
Common stock	—	—
Additional paid-in capital	1,752,048	1,722,012
Accumulated deficit	(1,652,869)	(1,330,545)
Accumulated other comprehensive loss	(27,468)	(28,612)
Total Precigen shareholders' equity	71,711	362,855
Noncontrolling interests	—	15,867
Total equity	71,711	378,722
Total liabilities and total equity	$ 455,763	$ 716,177

Precigen, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)

(Amounts in thousands, except share and per share data)	Three months ended December 31, 2019	Three months ended December 31, 2018	Year ended December 31, 2019	Year ended December 31, 2018
Revenues				
Collaboration and licensing revenues	$ (658)	$ 23,947	$ 14,059	$ 69,540
Product revenues	5,297	4,974	23,780	28,486
Service revenues	12,096	12,040	51,803	52,419
Other revenues	267	231	1,080	733
Total revenues	17,002	41,192	90,722	151,178
Operating Expenses				
Cost of products	7,800	7,531	31,930	35,087
Cost of services	7,611	6,462	29,471	27,589
Research and development	21,035	273,229	101,879	366,248
Selling, general and administrative	28,358	22,089	100,844	125,751
Impairment loss	30,184	—	30,810	—
Total operating expenses	94,988	309,311	294,934	554,675
Operating loss	(77,986)	(268,119)	(204,212)	(403,497)
Other Income (Expense), Net				
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net	5,221	(2,255)	8,291	(28,273)
Interest expense	(4,542)	(4,307)	(17,666)	(8,473)
Interest and dividend income	603	1,758	3,871	19,017
Other income (expense), net	2,774	(65)	3,445	470
Total other income (expense), net	4,056	(4,869)	(2,059)	(17,259)
Equity in net loss of affiliates	(473)	(913)	(2,416)	(8,986)
Loss from continuing operations before income taxes	(74,403)	(273,901)	(208,687)	(429,742)
Income tax benefit (expense)	905	(686)	930	15,425
Loss from continuing operations	$ (73,498)	$ (274,587)	$ (207,757)	$ (414,317)
Loss from discontinued operations, net of income tax benefit	(95,717)	(67,135)	(116,159)	(100,389)
Net loss	$ (169,215)	$ (341,722)	$ (323,916)	$ (514,706)
Net loss attributable to the noncontrolling interests	—	1,257	1,592	5,370
Net loss attributable to Precigen	$ (169,215)	$ (340,465)	$ (322,324)	$ (509,336)
Amounts Attributable to Precigen				
Net loss from continuing operations attributable to Precigen	$ (73,498)	$ (273,330)	$ (206,165)	$ (408,947)
Net loss from discontinued operations attributable to Precigen	(95,717)	(67,135)	(116,159)	(100,389)
Net loss attributable to Precigen	$ (169,215)	$ (340,465)	$ (322,324)	$ (509,336)
Net Loss per Share				
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$ (0.47)	$ (2.08)	$ (1.34)	$ (3.16)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted	(0.62)	(0.51)	(0.75)	(0.77)
Net loss attributable to Precigen per share, basic and diluted	$ (1.09)	$ (2.59)	$ (2.09)	$ (3.93)
Weighted average shares outstanding, basic and diluted	155,230,741	131,532,851	154,138,774	129,521,731

Precigen
4Q-2019 Business Update



2 March 2020

PRECIGEN

Forward-looking Statements

Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projections about future events and generally relate to plans, objectives and expectations for the development of Precigen's business and can be identified by forward-looking words such as "may," "will," "potential," "expect," "believe," "anticipate," "intend," "continue," "opportunity," "groundwork," "poised," "future," "update" and similar expressions. Examples of forward-looking statements in this presentation include statements about the timing, pace and progress of preclinical and clinical trials and discovery programs, potential benefits of platforms and product candidates including in comparison to competitive platforms and products, and future plans for the company's remaining non-healthcare assets. Although management believes that the plans, objectives and results reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, and actual future results may be materially different from the plans, objectives and expectations expressed in this presentation. These risks and uncertainties include, but are not limited to, (i) ongoing transition efforts following the company's recent divestment of several assets and businesses, (ii) Precigen's strategy and overall approach to its business model, its recent efforts to realign its business, and its ability to exercise more control and ownership over the development process and commercialization path; (iii) the ability to successfully enter new markets or develop additional products, including the expected timing and results of investigational studies and preclinical and clinical trials, whether with its collaborators or independently; (iv) the ability to successfully enter into optimal strategic relationships with its subsidiaries and operating companies that it may form in the future; (v) the ability to hold or generate significant operating capital, including through partnering, asset sales and operating cost reductions; (vi) actual or anticipated variations in operating results; (vii) actual or anticipated fluctuations in competitors' or collaborators' operating results or changes in their respective growth rates; (viii) cash position; (ix) market conditions in the company's industry; (x) the volatility of Precigen's stock price; (xi) the ability, and the ability of collaborators, to protect Precigen's intellectual property and other proprietary rights and technologies; (xii) the ability, and the ability of collaborators, to adapt to changes in laws or regulations and policies; (xiii) outcomes of pending and future litigation; (xiv) the rate and degree of market acceptance of any products developed by Precigen, its subsidiaries, collaborations or joint ventures; (xv) the ability to retain and recruit key personnel; (xvi) expectations related to the use of proceeds from public offerings and other financing efforts; (xvii) estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xviii) the challenges inherent in leadership transitions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Precigen's Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Precigen's subsequent filings with the Securities and Exchange Commission. All information in this presentation is as of the date its cover page, and Precigen undertakes no duty to update this information unless required by law.

All of the pharmaceutical products described in this presentation are investigational new drugs, which are currently undergoing pre-clinical and/or human clinical trial testing. As a result, none of them have had their safety or efficacy established or are approved by the U.S. Food and Drug Administration or any other regulatory agency.

Precigen: Setting the Stage for Success



Adhering to Operating Principles to Deliver Value to All Stakeholders

PRECIGEN'S VISION FOR PATIENTS

Develop life-saving and cost-conscious therapies utilizing our cutting-edge platform technologies for patients with unmet need

FISCAL STRENGTH

Responsible capital allocation to ensure runway for maximum value creation

ACTIVE PORTFOLIO MANAGEMENT

Continuous evaluation of portfolio based on data to make rapid go/no go decisions

RAPID EXECUTION

Focus on rapid execution of priority programs with the highest probability of success

STRATEGIC PARTNERSHIPS

Seek strategic partnerships to maximize value generation

Our Non-Healthcare Asset Strategy

Trans Ova Genetics

Continue to evaluate strategic alternatives

Increase operational efficiencies

Contribute cash to Precigen

MBP Titan

Significantly reduce cash requirement

Increase operational efficiencies

Support partnering discussions

One Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs

UltraCAR-T



- Non-viral multi-gene delivery
- Non-exhausted, stem-like T cell phenotype
- Higher antigen-specific expansion
- Enhanced *in vivo* persistence
- Ability to deplete with kill switch
- Overnight manufacturing process

AdenoVerse Immunotherapy



- Large payload capacity
- Low seroprevalence in humans
- Ability for repeat administration
- Durable antigen-specific immune response
- Highly productive manufacturing process

ActoBiotics



- Food-grade bacteria, *L. lactis*
- Long history of safe use in humans
- Easy genetic manipulation
- Cost-effective and scalable manufacturing
- Convenient oral or topical delivery
- Local expression of genes at disease site

Robust Pipeline with Many Milestones to Drive Value

	PRODUCT	PLATFORM	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	STATUS / MILESTONES	PARTNER
PRECIGEN	**AG019**	ActoBiotics	Type 1 Diabetes						Interim data in 3Q20	
	PRGN-3005	UltraCAR-T	Ovarian Cancer						Initial data in 2H20	
	PRGN-3006	UltraCAR-T	AML, MDS						Initial data in 2H20	
	INXN-4001	Non-viral UltraVector	Heart Failure						Phase 1 data in 2020	
	PRGN-2009	OTS AdenoVerse Immunotherapy	HPV+ Solid Tumors						Initiate Phase 1 in 2020	
PARTNERED	**FCX-007**	Fibroblast Cell Therapy	RDEB						Pivotal Phase 3 initiated	CASTLE CREEK PHARMA
	AG013	ActoBiotics	Oral Mucositis						Phase 2 interim data in 1H20	ORAGENICS
	CGF166	Gene Therapy	Hearing Loss						Phase 1/2 ongoing	NOVARTIS
	FCX-013	Fibroblast Cell Therapy	Localized Scleroderma						Phase 1/2 is enrolling	CASTLE CREEK PHARMA

Our UltraCAR-T™ Platform Promises a More Effective Way to Treat Patients

Conventional CAR-T

Viral vectors and *ex vivo* expansion result in long delays for patient treatment and high cost



- Reliance on viral vectors
  - Complexity of manufacturing viral vectors
- Long and complex CAR-T cell manufacturing process
  - Long delays for patients
  - High cost of manufacturing
- Exhausted T cell phenotype
- Major challenges in solid tumor treatment

UltraCAR-T™

Overnight non-viral gene transfer eliminates long delays for patient treatment and lower manufacturing cost



- Non-viral gene delivery
  - Simplified manufacturing of Plasmid DNA
- Overnight UltraCAR-T manufacturing process
  - No *ex vivo* expansion necessary
  - Reduced manufacturing cost
- Stem-like memory T cell phenotype
- Enhanced potential for expansion and persistence

PRGN-3005, a first-in-class therapy in ovarian cancer



- Phase 1 trial is ongoing
  - Arm A: Intraperitoneal (IP) infusion; Arm B: Intravenous (IV) infusion
  - Second cohort for IP arm currently enrolling patients
- 100% manufacturing success to date
- Encouraging preliminary findings of UltraCAR-T kinetics
- Initial data readout from IP arm expected in 2H20



Infusion of PRGN-3005 UltraCAR-T into intraperitoneal cavity allows for direct access to tumor antigen expressed on cancer cells

PRECIGEN

PRGN-3006, a first-in-class therapy in AML



- Phase 1/1b trial is ongoing
  - Arm 1: No Lymphodepletion ; Arm 2: With Lymphodepletion
  - Second cohort for Arm 1 and First cohort for Arm 2 currently enrolling
- 100% manufacturing success to date
- Encouraging preliminary findings of UltraCAR-T kinetics
- Initial data readout expected in 2H20



PRECIGEN

Multiple Milestones to Drive Value in 2020 and Beyond

- Initial data from IP arm of PRGN-3005 UltraCAR-T™ Phase 1 trial in Ovarian Cancer
- Initial data from PRGN-3006 UltraCAR-T™ Phase 1 trial in AML and MDS
- Interim data from Phase 2 trial of AG013 in Oral Mucositis
- Interim data from Phase 1b/2a trial of AG019 in Type 1 Diabetes
- Phase 1 data completion of INXN-4001 in Heart Failure patients with LVAD
- Initiate Phase 1 trial of PRGN-2009 off-the-shelf AdenoVerse™ immunotherapy in HPV+ cancers

ADVANCING MEDICINE WITH PRECISION™